Abstract
In recent years, the indications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been expanded due to the improvement of transplant technique. More attentions have been paid to donor specific anti-human leukocyte antigen antibodies because of the widely application of haploidentical SCT. Relapse remains a hot topic in patients with hematological malignancies who underwent allo-HSCT. Here, the progress of allo-HSCT is discussed according to some reports from 59th American Society of Hematology (ASH) Annual Meeting. Key words: Hematopoietic stem cell transplantation; Donor specific anti-human leukocyte antigen antibodies; Indication; Relapse
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
